Therapy with pegylated (40 KDa) interferon alfa-2a (PEGASYS) significantly enhances quality of life compared with standard interferon alfa-2a (ROFERON-A) in patients with chronic hepatitis C - Rasenack,J.; Zeuzem,S.; Feinman,S.V. (Hepatology, 2000)